Zoetis Inc. shares ended Friday's trading session at $74.22, marking a decline of 1.67% and establishing a new 52-week low of $72.38. The stock has now fallen approximately 33% from its May 6 close of $111.22, as the animal health giant struggles with weak first-quarter results and a lowered full-year 2026 guidance.
The company reported first-quarter revenue of $2.262 billion, a 3% increase on a reported basis, but flat on an organic operational basis when excluding currency fluctuations and merger-related effects. Adjusted earnings per share came in at $6.85 to $7.00, down from prior expectations. Management also reduced its 2026 revenue outlook to a range of $9.680 billion to $9.960 billion, citing persistent headwinds in the U.S. companion animal segment.
CEO Kristin Peck described the first quarter as "more challenging than anticipated," pointing to increased price sensitivity among pet owners, a decline in veterinary visits, and heightened competition in key therapeutic areas such as dermatology and parasiticides. These categories represent core revenue drivers for Zoetis, making the downturn particularly concerning for investors.
U.S. companion animal sales dropped 11% during the quarter, a significant blow given that this segment has historically been a growth engine. International revenue, however, rose 10% on an organic basis, while the livestock division showed relative stability. Despite these bright spots, the market's focus remained squarely on the softening domestic pet-care market and the company's cautious forward guidance.
Chief Financial Officer Wetteny Joseph noted on the earnings call that "price continues to be a key differentiator" in the current environment. He also revealed that global organic operational revenue would have declined 5% if not for approximately $100 million in revenue pulled forward due to fiscal-year alignment.
Wall Street analysts responded with a wave of target cuts. Morgan Stanley reduced its price target on Zoetis to $115 from $160, though it maintained an Overweight rating. William Blair analyst Brandon Vazquez described the new guidance as a "heavy lift" and noted that he saw "no signs of improvement" in pet-owner spending. During the earnings call, Vazquez pressed management on whether the market was becoming "less durable and less attractive" for the company.
Competitive pressures are intensifying. Elanco Animal Health received FDA approval for its dermatology drug Zenrelia in 2024, positioning it as a direct challenger to Zoetis's blockbuster Apoquel for canine skin disease. Elanco has indicated it will price Zenrelia roughly 20% below Apoquel. Additionally, Elanco's Credelio Quattro has entered the parasite treatment market, competing directly with Zoetis's Simparica Trio.
The broader market also faced headwinds on Friday, with animal health and diagnostics stocks mostly lower. IDEXX Laboratories fell 0.75%, while Elanco tumbled 8.25%. Zoetis saw elevated trading volume of approximately 9 million shares, reflecting heightened investor attention.
Looking ahead to Monday's open, traders will be watching for any signs of buyer interest near the $72.38 low. A break below that level could push the stock into uncharted territory, while a recovery above Thursday's close of $75.48 might suggest selling pressure is easing. However, the near-term outlook remains cautious. If pet owner spending continues to soften, promotional pressures persist, or Zoetis is forced to lower guidance again, the stock could face further downside even after the steep decline. Investors will need to see concrete evidence of stabilizing veterinary visits and a stronger contribution from livestock and international operations to regain confidence.
